4 recruiting, 2 completed, 1 active not recruiting, 1 not yet recruiting. 6 Not applicable, 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 6 | Recruiting 4, Not yet recruiting 1, Unknown 1 |
| Phase 4 | 3 | Completed 2, Active not recruiting 1 |
Follow Treatment Resistant Schizophrenia: new trials by email Literature Review of Treatment Resistant Schizophrenia trials Research Report on Treatment Resistant Schizophrenia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effectiveness of Exercise Alone and tDCS+Exercise on Cognitive Function Improvement in Patients With Treatment Resistant Schizophrenia Aerobic Exercise, Stretching/Education Control, Active tDCS - Schizophrenia, Treatment Resistant Schizophrenia | Not applicable | Not yet recruiting | Kit Wa Chan | 160 | 2026-02-23 | 2026-02-11 |
| Effects of Nitraria Retusa Infusion on Clozapine-induced Metabolic Side Effects The Nitraria retusa arm - Treatment Resistant Schizophrenia, Obesity & Overweight | Not applicable | Recruiting | Faculty of Medicine, Sousse | 30 | 2026-01-03 | 2026-09-14 |
| Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR. Group A: (Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol,anxiolytics: clonazepam, stedon, tavor antidepressants: seropram),, Group B (Pharmacotherapy and TAU) (Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol, clonazepam, stedon, tavor, antidepressants,, Group C (Pharmacotherapy and Psychotherapy) Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol, clonazepam, stedon, tavor, lithium, depakine - Treatment Resistant Schizophrenia, Treatment Resistant Bipolar Disorder | Phase 4 | Active not recruiting | Dr. Stavroula Rakitzi | 84 | 2025-06-04 | 2026-05-01 |
| Magnetic Seizure Therapy for Schizophrenia - Trial Magnetic Seizure Therapy (MST), Electroconvulsive Therapy (ECT) - Treatment Resistant Schizophrenia, Schizophrenia | Not applicable | Recruiting | Centre for Addiction and Mental Health | 80 | 2025-04-22 | 2026-02-03 |
| Maintenance ElectroConvulsive Therapy in Clozapine RESISTant Schizophrenia - the MECT-RESIST Trial maintenance electroconvulsive therapy (mECT) - Schizophrenia, Treatment Resistant Schizophrenia | Not applicable | Recruiting | Central Institute of Mental Health, Mannheim | 140 | 2025-02-14 | 2026-02-03 |
| Reduction of Auditory-Verbal Hallucinations in Schizophrenia Through Cortical Neuromodulation Active Transcranial Magnetic Stimulation (TMS), Sham Transcranial Magnetic Stimulation (TMS) - Treatment Resistant Schizophrenia | Not applicable | Recruiting | Centre Hospitalier St Anne | 20 | 2024-05-21 | 2026-09-21 |
| Dextromethorphan as an Augmentation Agent in Treatment-resistant Schizophrenia Dextromethorphan, Placebo - Treatment Resistant Schizophrenia | Phase 4 | Completed | All India Institute of Medical Sciences, Bhubaneswar | 40 | 2023-08-31 | 2025-05-09 |
| Effect of Atenolol Versus Ivabradine on HRV in TRS Patients on Clozapine With Tachycardia: A Randomised Control Trial. Atenolol 25 mg, Ivabradine 10mg - Treatment Resistant Schizophrenia, Clozapine Adverse Reaction | Not applicable | Unknown | All India Institute of Medical Sciences, Bhubaneswar | 40 | 2023-08-01 | 2024-07-17 |
| Comparison of Maintenance ECT Versus Clozapine in Treatment-resistant Schizophrenia Bilateral M-ECT, Clozapine - Treatment Resistant Schizophrenia | Phase 4 | Completed | All India Institute of Medical Sciences, Bhubaneswar | 60 | 2019-02-01 | 2021-06-16 |
Schizophrenia, Treatment-Resistant (9) · Schizophrenia (3) · Cognitive Dysfunction (1) · Metabolic Syndrome (1) · Obesity (1) · Obesity, Abdominal (1) · Overweight (1) · Psychotic Disorders (1) · Tachycardia (1)
Mental Disorders (9) · Schizophrenia Spectrum and Other Psychotic Disorders (9) · Schizophrenia (6) · Pathological Conditions, Signs and Symptoms (2) · Arrhythmias, Cardiac (1) · Body Weight (1) · Cardiac Conduction System Disease (1) · Cardiovascular Diseases (1) · Cognition Disorders (1) · Glucose Metabolism Disorders (1) · Heart Diseases (1) · Hyperinsulinism (1) · Insulin Resistance (1) · Metabolic Diseases (1) · Neurocognitive Disorders (1)
Clozapine (2) · Antidepressive Agents (1) · Aripiprazole (1) · Atenolol (1) · Citalopram (1) · Clonazepam (1) · Clopenthixol (1) · Dextromethorphan (1) · Drug Therapy (1) · Exercise (1) · Ivabradine (1) · Lithium (1) · Olanzapine (1) · Paliperidone Palmitate (1) · Psychotherapy (1)
All India Institute of Medical Sciences, Bhubaneswar (3) · Central Institute of Mental Health, Mannheim (1) · Centre Hospitalier St Anne (1) · Centre for Addiction and Mental Health (1) · Dr. Stavroula Rakitzi (1) · Faculty of Medicine, Sousse (1) · Kit Wa Chan (1)
India (3) · Canada (1) · France (1) · Germany (1) · Greece (1) · Hong Kong (1) · Tunisia (1)
Alexander Sartorius, Prof (1) · Biswa Ranjan Mishra, MD (1) · Daniel Blumberger, M.D., MSc. (1) · Dr. Polyxeni Georgila, M. D. (1) · Dr. Stavroula Rakitzi, PhD (1) · Kit Wa Chan, MD (1) · Philippe Domenech, MD, PhD (1) · Saad Saguem, Professor (1)
PMID 10372604, PMID 10492856, PMID 15968344, PMID 16380684, PMID 16633199, PMID 17187911, PMID 19837567, PMID 25157964, PMID 25400359, PMID 25697225, PMID 26827129, PMID 27919182, PMID 28096876, PMID 29732913, PMID 35556138, PMID 40420043, PMID 41780197, PMID 42567080, PMID 9137112, PMID 9541337